Tel Aviv University Neuroimmunology Laboratory
Treatment to Prevent Cancer Recurrence
and Metastatic Disease
Colon and rectal cancer clinical research
Innovative research treatment for colon or rectal cancer patients who are candidates for tumor resection surgery.
The aim of the treatment is to prevent cancer recurrence and prevent the development of cancer metastases.
-
The treatment is provided free of charge.
-
The drug treatment in the study is not a substitute for existing treatments.
-
Treatment begins 5 days before surgery and continues for about two weeks afterward.
-
The treatment is based on existing drugs marketed in Israel and internationally.
-
Patients diagnosed with primary Colorectal cancer, at stages 1–3 (with no evidence of metastases).
-
Patients who are candidates for surgical tumor resection
-
Women and men aged 20 to 85
Who the research is intended for
Who the research is not intended for
-
Patients who have already undergone tumor resection surgery.
-
Patients who regularly consume beta-blocker or NSAID medications or are sensitive to these medications.
-
Patients with malignancy treated in the last 5 years
-
Patients with active asthma
Medical centers where
The research is underway.
-
Shamir Medical Center (Asaf Harofeh), Tzirifin.
-
Principal Investigator: Prof. Oded Zamora.
-
Hadassah Medical Center, Jerusalem.
-
Principal Investigator: Dr. Noam Shusman.
-
Hasharon Medical Center, Petach Tikva.
-
Principal Investigator: Prof. Nidal Issa.
*A full examination regarding eligibility for the study will be conducted at the medical center.
When you arrive at your next appointment with your doctor, ask him/her about joining the study!